SOURCE-LINKED STUDY SUMMARY
Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance.
Abstract summarizedQuality not appraised
- What was studied
- An open-label randomized trial examined thymosin alpha-1, survival and immune-cell changes in severe liver disease.
- Who / model studied
- 73 patients with hepatitis B-related acute-on-chronic liver failure, 35 receiving thymosin alpha-1 and 38 standard care alone.
- Studied dose & schedule
- Thymosin alpha-1 added to standard medical therapy; dose, route and treatment duration were not stated in the abstract.
- What the study found
- The authors reported higher 90-day transplant-free survival, fewer regulatory T-cell subsets and moderated late inflammatory responses. The abstract did not provide absolute survival rates or effect uncertainty.
- Limitations & context
- Abstract-based assessment of a small, unblinded disease-specific trial. It does not establish generic immune enhancement in healthy people; regimen and detailed safety could not be assessed.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1080/08923973.2026.2641686